Abstract:Background. The discovery of the presence of fetal genetic material in maternal blood has opened up a new approach to prenatal diagnosis. One approach that has been extensively investigated over the past few decades is the isolation of fetal cells from maternal blood (Herzenberg et al. Proc Natl Acad Sci USA. 1979;76:1453-5; Bianchi et al. Proc Natl Acad Sci USA. 1990;87:3279-83; Cha et al. Prenat Diagn. 2005-25:586-91). As the fetal cells are scarce and the enrichment is of low efficiency, the technique could not be implemented in clinics. In 1997, Lo et al. (Lancet 1997-350(9076):485-7) discovered that cell-free fetal DNA is present in the plasma and serum of pregnant women. This discovery suggests that maternal plasma/serum DNA may be a useful source of material for non-invasive prenatal diagnosis. The objective of our study was to investigate the feasibility of using fetal DNA in maternal plasma for prenatal diagnosis. Methods. Plasma DNA in 277 blood samples of 40 pregnant women at the gestational period from 5 to 40 weeks and 24 h after delivery were extracted by column separation. FQ-PCR was used to amplify the SRY sequence in 237 plasma samples of 30 pregnant women. Fluorescent PCR was used to amplify 9 short tandem repeat loci simultaneously in 40 plasma samples of 10 pregnant women, and genomic DNA samples from their husbands were amplified by the same method. Results. The fetal SRY sequence could be detected from the 7th week of gestation, with a concentration that increased with progressing gestational age, attaining its highest peak before delivery. Twenty-four hours after delivery, fetal SRY sequence could not be detected in the maternal plasma. The concordance rate of the SRY sequence amplification results of plasma-free DNA, with real fetal gender was 100%. Analysis of maternal plasma samples collected during pregnancy revealed the presence of paternally inherited fetal-specific alleles. Among the 30 collected plasma samples, fetal-specific alleles were detected in 23 plasma DNA samples. The rate of positive results was 76% (23/30), and the frequency of positive results was 6/10 in early pregnancy, 8/10 in middle pregnancy, and 9/10 in late pregnancy. Short tandem repeats could not be detected from the maternal plasma 24 h after delivery. Conclusion. Fluorescent PCR can be used for amplification of fetal SRY sequence and STRs in maternal plasma to obtain fetal genetic information, which may have implications for non-invasive prenatal diagnosis of certain hereditary diseases.

Detection Efficiency of Fetal Epigenetic Marker in Maternal Plasma

Quantification And Application Of The Placental Epigenetic Signature Of The Rassf1a Gene In Maternal Plasma

A method for noninvasive detection of fetal large deletions/duplications by low coverage massively parallel sequencing.

Quantification of Fetal DNA by Using Methylation-Based Discrimination

Feasibility Study of Using Fetal DNA in Maternal Plasma for Non‐invasive Prenatal Diagnosis

A noninvasive method for the detection of foetal DNA in early pregnancy based on differential methylation pattern of Ras association domain family member 1A

Differentially methylated regions of C21orf25 between maternal and fetal DNA:implication for noninvasive prenatal diagnosis

Noninvasive Prenatal Diagnosis Implication of Differentially Methylated DNA in Noninvasive Prenatal Diagnosis.

Detection of Circulating Fetal DNA in Maternal Plasma for Non-Invasive Prenatal Diagnosis

Detection of Fetal Dna in Maternal Plasma by Microarray Coupled with Emulsions Pcr

Quantitative Detection of the Hypermethylated RASSF1A Gene in Maternal Plasma of Pre-Eclampsia

Detection of fetal SRY gene from cell-free fetal DNA in maternal peripheral blood

Diagnosis of fetal chromosomal aneuploidy by free fetal DNA in maternal plasma in the first trimester

Quantitative detection of sex chromosomal for non-invasive prenatal screening of sex-linked inheritable disease

Examination of Fetal Sex in the Peripheral Blood of Pregnant Women before 9 Completed Weeks' Gestation

Non-invasive Prenatal Diagnosis of Trisomy 21 by Dosage Ratio of Fetal Chromosome-Specific Epigenetic Markers in Maternal Plasma

Microarray-Based Method to Analyze DNA Methylation of Maternal Plasma in Pregnant Women

Noninvasive Prenatal Analysis by Multiplex Fluorescent Pcr of Maternal Plasma Dna

Study of Detecting Fetal DNA from Mutual plasma for Prenatal Diagnosis

Highly Sensitive and Specific Detection of SRY Gene for Non–invasive Prenatal Diagnosis

Application of cell-free fetal DNA in maternal plasma for non-invasive prenatal diagnosis of fetal sex by of improved polymerase chain reaction techniques